$266 Thousand is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 52 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EOCWU | ELLIOTT OPPORTUNITY II CORP | $20,180 | -99.9% | 2,000,000 | 0.0% | 7.60% | +2.6% | |
IMTX | IMMATICS NV | $6,075 | -99.9% | 697,431 | 0.0% | 2.29% | -12.5% | |
TXN | TEXAS INSTRUMENTS INC | $5,287 | -99.9% | 32,000 | 0.0% | 1.99% | +7.2% | |
VT | VANGUARD TOT WORLD STK ETFetfs | $2,550 | -99.9% | 29,585 | 0.0% | 0.96% | +9.7% | |
BOND | PIMCO ACTIVE BOND EXCHANGE-T | $1,403 | -99.9% | 15,502 | 0.0% | 0.53% | +1.3% | |
CDAK | CODIAK BIOSCIENCES INC | $337 | -99.9% | 847,108 | 0.0% | 0.13% | -48.8% | |
APEN | APOLLO ENDOSURGERY INC | $311 | -99.8% | 31,202 | 0.0% | 0.12% | +82.8% | |
AGLE | AEGLEA BIOTHERAPEUTICS INC | $111 | -99.9% | 245,678 | 0.0% | 0.04% | -12.5% | |
LXRX | LEXICON PHARMACEUTICALS INC | $68 | -99.9% | 35,714 | 0.0% | 0.03% | -18.8% | |
TFFP | TFF PHARMACEUTICALS INC | $23 | -100.0% | 22,066 | 0.0% | 0.01% | -73.5% | |
PLXP | PLX PHARMA INC | $21 | -100.0% | 125,346 | 0.0% | 0.01% | -73.3% | |
POR | PORTLAND GENERAL ELECTRIC CO | $6 | -99.9% | 118 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-01 |
3 | 2024-04-30 |
13F-HR | 2024-04-30 |
144 | 2024-04-29 |
SC 13G | 2024-03-05 |
13F-HR | 2024-02-28 |
SC 13G | 2024-02-14 |
13F-HR | 2023-11-09 |
13F-HR | 2023-08-04 |
3 | 2023-06-02 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.